我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

骨保护素不同层面对内皮细胞的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第6期
页码:
649-653
栏目:
基础研究
出版日期:
2013-11-25

文章信息/Info

Title:
Effect of osteoprotegerin on endothelial cells
作者:
杨佳伟1; 饶利亚2; 毛 奕2; 李裕舒2
(1.荆州市中心医院心内科，湖北 荆州 434020；2.华中科技大学同济医学院附属协和医院心研所，湖北 武汉 430022)
Author(s):
YANG Jia wei1;  RAO Li ya2;  MAO Yi2;  LI Yu shu2
(1.Department of Heart Diseases, Jingzhou Center Hospital, Jinzhou 434020, Hubei, China; 2.Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China)
关键词:
骨保护素; 动脉粥样硬化; 内皮细胞
Keywords:
osteoprotegerin;  atherosclerosis;  endothelial cell;  eNOS
分类号:
R543.5
DOI:
-
文献标识码:
A
摘要:
目的:观察骨保护素(OPG)作为始动因素对人内皮细胞的数量变化及内皮型一氧化氮合酶 (endothelial nitric oxide synthase，eNOS)和一氧化氮(NO)产生的影响。方法:常规培养永生化的人内皮细胞，以不同浓度（0、0.5、1.0、2.0、4.0、6.0、8.0、10.0及100.0 ng/ml，共9组）的OPG作用细胞48 h后，用细胞计数试剂盒8（cell count kit，CCK8）来检测细胞的数量及NO检测试剂盒检测NO的产量。用免疫细胞化学染色法检测eNOS蛋白表达的水平，实时定量PCR检测eNOS基因的定量表达。结果: 与对照组的细胞数（0.759±0.067）相比，8.0 ng/ml OPG组的细胞数为(1.091±0.200），P<0.05，10.0 ng/ml OPG组的细胞数为(1.103±0.152)及100.0 ng/ml OPG组的细胞数为（1.231±0.192），均P<0.01。8.0 ng/ml OPG组NO生成量为(102224±0612) μmol/L(P<0.05），10.0 ng/ml OPG组NO生成量为(117.183±0.552) μmol/L和1000 ng/ml OPG组NO生成量为(128.216±0.492) μmol/L（均P<0.01）。同时eNOS蛋白及eNOS mRNA的表达量在6.0 ng/ml、8.0 ng/ml、10.0 ng/ml及100.0 ng/ml OPG组均显著地呈浓度依赖性增加（均P<0.01）。结论:OPG具有促进内皮细胞增殖效应，可能在抗动脉粥样硬化过程中有一定意义，且与浓度梯度呈明显的正相关。
Abstract:
AIM:To observe the effects of osteoprotegerin (OPG) as an initiating factor on the changes in the number of endothelial cells and on nitric oxide synthase (eNOS) and nitric oxide (NO). METHODS: Immortalized human endothelial cells were conventionally cultured and then treated with different concentrations of OPG (0, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 and 100.0 ng/ml, total nine groups) for 48 h. Number of cells was detected with the cell count kit (CCK-8). Nitric oxide production was detected with nitric oxide detection kit, eNOS protein expressions was examined with immunocytochemical method and the level of eNOS mRNA was assayed with realtime quantitative PCR. RESULTS: Compared with the number (0.759±0.067) in control group, the number of endothelial cells gradually increased with the increase of OPG within the physiological concentration range. The increased number of cells in 8.0 ng/ml group and higher concentration groups were statistically significant, (1.091±0.200) in 8.0 ng/ml group (P<0.05), (1.103±0.152) in 10.0 ng/ml group (P<0.01) and (1.231±0.192) in 100.0 ng/ml group (P<0.01). NO increased synchronously with the proliferation of endothelial cells and also reached statistical significance in 8.0 ng/ml and higher groups (102.224±0.612) in 8.0 ng/ml group (P<0.05), (117.183 ± 0.552) in 10.0 ng/ml group (P<0.01) and (128216±0.492) in 100.0 ng/ml group (P<0.01). eNOS protein and mRNA expression in 6.0 ng/ml, 8.0 ng/ml, 100 ng/ml and 1000 ng/ml groups increased significantly in a concentration dependent manner (P<0.01). CONCLUSION: OPG within the human physiological concentration range promotes endothelial cell proliferation. During the process of antiatherosclerosis, OPG may promote endothelial cell repair and the effect is positively correlated with the OPG concentration gradient.

参考文献/References

[1]Blair JM,Zheng Y,Dunstan CR.RANK ligand[J].Int J Biochem Cell Biol,2007,39(6):1077-1081.
[2]Omland T,Ueland T,Jansson AM,et al.Circulating osteoprotegerin levels and longterm prognosis in patients with acute coronary syndromes[J].J Am Coll Cardiol,2008,51(6):627-633.
[3]Anand DV,Lahiri A,Lim E,et al.The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects[J].J Am Coll Cardiol,2006,47(9):1850-1857.
[4]Anand DV,Lim E,Darko D,et al.Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers[J].J Am Coll Cardiol,2007,50(23):2218-2225.
[5]Joshi MS,Ferguson TB Jr,Johnson FK,et al.Receptormediated activation of nitric oxide synthesis by arginine in endothelial cells[J].Proc Natl Acad Sci USA,2007,104(24):9982-9987.
[6]Kuhhncordt PJ,Gyurko R,Hart F,et al.Accelerated atherosclerosis aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase doubleknockout mice[J].Circulation,2001,104(4):448-454.
[7]Lund DD,Faraci FM,Miller FJ,et al.Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits[J].Circulation,2000,101(9):1027-1033.
[8]Persson K,Sauma L,S?fholm A,et al.LDL and UVoxidized LDL induce upregulation of iNOS and NO in unstimulated J774 macrophages and HUVEC?Apmis, 2009,117(1):1-9.
[9]Asanuma Y,Chung CP,Oeser A,et al.Serum osteoprotegerin is increased and independently associated with coronaryartery atherosclerosis in patients with rheumatoid arthritis[J].Atherosclerosis,2007,195(2):e135-e141.
[10]Sandberg WJ,Yndestand A,?ie E,et al.Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization[J].Arterioscler Thromb Vasc Biol,2006,26(4):857-863.
[11]Cross SS,Yang Z,Brown NJ,et al.Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumor angiogenesis? [J].Int J Cancer,2006,118(8):1901-1908.
[12]Malyankar UM,Scatena M,Suchland KL,et al.Osteoprotegerin is an alpha vbeta 3-induced,NF-kappa B-dependent survival factor for endothelial cells[J].J Biol Chem,2000,275(28):20959-20962.
[13]Pritzker LB,Scatena M,Giachelli CM.The role of osteoprotegerin and tumor necrosis factorrelated apoptosisinducing ligand in human microvascular endothelial cell survival[J].Mol Biol Cell,2004,15(6):2834-2841.
[14]Augoulea A,Vrachnis N,Lambrinoudaki I.Osteoprotegerin as a marker of atherosclerosis in diabetic patients[J].Int J Endocrinol,2013,2013:182060.
[15]Giaginis C, Papadopouli A,Zira A,et al.Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis[J].Med Sci Monit,2012,18(10):CR597-CR604.

备注/Memo

备注/Memo:
收稿日期：2013-04-15.通讯作者：饶利亚，主管技师，主要从事动态心电学在临床心血管疾病诊断中的信息地位与科学研究 Email：lwly413@yahoo.com.cn 作者简介：杨佳伟，主治医师，硕士 Email：yangweijy@sohu.com
更新日期/Last Update: 2013-11-20